Lv41
572 积分 2023-10-22 加入
Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis
1个月前
已完结
Global burden of metabolic dysfunction-associated steatotic liver disease, 1990–2023, and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2023
1个月前
已完结
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
1个月前
已完结
Metabolic dysfunction-associated steatotic liver disease in adults
1个月前
已完结
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults
1个月前
已完结
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
1个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2个月前
已完结
Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model
2个月前
已完结
Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders
2个月前
已完结
Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine
2个月前
已完结
皖公网安备34019202002308
